| Primary |
| Product Used For Unknown Indication |
44.8% |
| Blood Cholesterol Increased |
19.4% |
| Hypercholesterolaemia |
9.0% |
| Acute Myocardial Infarction |
4.5% |
| Cellulitis |
3.0% |
| Low Density Lipoprotein Increased |
3.0% |
| Myocardial Ischaemia |
3.0% |
| Antiplatelet Therapy |
1.5% |
| Blood Cholesterol |
1.5% |
| Blood Cholesterol Decreased |
1.5% |
| Coronary Artery Disease |
1.5% |
| Dyslipidaemia |
1.5% |
| Hypertension |
1.5% |
| Niddm |
1.5% |
| Osteomyelitis Chronic |
1.5% |
| Prophylaxis |
1.5% |
|
| Rhabdomyolysis |
14.8% |
| Myalgia |
7.4% |
| Product Substitution Issue |
7.4% |
| Pruritus |
7.4% |
| Weight Decreased |
7.4% |
| Abdominal Pain Upper |
3.7% |
| Alopecia |
3.7% |
| Blood Pressure Increased |
3.7% |
| Continuous Haemodiafiltration |
3.7% |
| Drug Intolerance |
3.7% |
| Dysstasia |
3.7% |
| Exposure Via Partner |
3.7% |
| General Physical Health Deterioration |
3.7% |
| Hallucinations, Mixed |
3.7% |
| Memory Impairment |
3.7% |
| Musculoskeletal Discomfort |
3.7% |
| Myocardial Infarction |
3.7% |
| Myopathy |
3.7% |
| Myositis |
3.7% |
| Overdose |
3.7% |
|
| Secondary |
| Product Used For Unknown Indication |
42.0% |
| Hypercholesterolaemia |
14.9% |
| Blood Cholesterol Increased |
7.7% |
| Hypertension |
7.7% |
| Anaesthesia |
3.3% |
| Rheumatoid Arthritis |
2.8% |
| Antiplatelet Therapy |
2.2% |
| Cerebrovascular Accident Prophylaxis |
2.2% |
| Drug Use For Unknown Indication |
2.2% |
| Ischaemic Heart Disease Prophylaxis |
2.2% |
| Pain |
2.2% |
| Coronary Artery Disease |
1.7% |
| Asthma |
1.1% |
| Cardiovascular Event Prophylaxis |
1.1% |
| Cholesterol High |
1.1% |
| Chronic Obstructive Pulmonary Disease |
1.1% |
| Duodenal Ulcer |
1.1% |
| Dyslipidaemia |
1.1% |
| Functional Gastrointestinal Disorder |
1.1% |
| Low Density Lipoprotein Increased |
1.1% |
|
| Colitis Microscopic |
8.3% |
| Dyspnoea |
8.3% |
| Toxicity To Various Agents |
8.3% |
| Vomiting |
8.3% |
| Liver Injury |
5.6% |
| Polymyositis |
5.6% |
| Pruritus |
5.6% |
| Renal Disorder |
5.6% |
| Rhabdomyolysis |
5.6% |
| Upper Gastrointestinal Haemorrhage |
5.6% |
| Weight Decreased |
5.6% |
| Wound Infection Staphylococcal |
5.6% |
| Blood Bilirubin Increased |
2.8% |
| Blood Potassium Increased |
2.8% |
| Completed Suicide |
2.8% |
| Diabetes Mellitus |
2.8% |
| Diarrhoea |
2.8% |
| Drug Interaction |
2.8% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
2.8% |
| Epistaxis |
2.8% |
|
| Concomitant |
| Product Used For Unknown Indication |
42.1% |
| Hypertension |
14.0% |
| Chronic Myeloid Leukaemia |
4.9% |
| Depression |
4.9% |
| Type 2 Diabetes Mellitus |
4.9% |
| Plasma Cell Myeloma |
2.8% |
| Prophylaxis |
2.8% |
| Bipolar Disorder |
2.5% |
| Actinic Keratosis |
2.1% |
| Myocardial Ischaemia |
2.1% |
| Urinary Tract Infection |
2.1% |
| Acute Myocardial Infarction |
1.8% |
| Coronary Artery Disease |
1.8% |
| Drug Use For Unknown Indication |
1.8% |
| Lung Neoplasm Malignant |
1.8% |
| Multiple Sclerosis |
1.8% |
| Thrombosis Prophylaxis |
1.8% |
| Atrial Fibrillation |
1.4% |
| Epilepsy |
1.4% |
| Myelodysplastic Syndrome |
1.4% |
|
| Ventricular Tachycardia |
8.7% |
| Paraesthesia |
7.6% |
| Vision Blurred |
7.6% |
| Vomiting |
6.5% |
| Weight Decreased |
6.5% |
| Renal Failure Acute |
5.4% |
| Tremor |
5.4% |
| Urosepsis |
5.4% |
| Pancreatitis |
4.3% |
| Pulmonary Oedema |
4.3% |
| Somnolence |
4.3% |
| Treatment Failure |
4.3% |
| Upper Gastrointestinal Haemorrhage |
4.3% |
| Urticaria |
4.3% |
| Weight Increased |
4.3% |
| Drug Ineffective |
3.3% |
| Headache |
3.3% |
| Nausea |
3.3% |
| Oedema Peripheral |
3.3% |
| Osteonecrosis Of Jaw |
3.3% |
|
